Action ARWR ARROWHEAD PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Arrowhead Pharmaceuticals, Inc.

Actions

ARWR

US04280A1007

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 21/06/2024 		Varia. 5j. Varia. 1 janv.
25,5 USD +7,19% Graphique intraday de Arrowhead Pharmaceuticals, Inc. -1,32% -16,67%
12/06 Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 04:00 PM
03/06 Le plozasiran d'Arrowhead Pharmaceuticals réduit les triglycérides dans un essai de phase 3 ; les actions augmentent MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
BU
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
BU
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
BU
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
BU
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
BU
Arrowhead Pharmaceuticals : TIDES USA 2024 TIDES 2024 AdiposeTIDES 2024 ARO-SOD1
PU
Arrowhead Pharmaceuticals : 2024 Second Quarter Results Prepared Remarks
PU
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
BU
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
BU
Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
BU
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
BU
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
BU
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
BU
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
BU
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BU
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
BU
Arrowhead Pharmaceuticals : 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference View Presentation
PU
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
BU
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
BU
Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
BU
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ARWR
  4. Actualités Arrowhead Pharmaceuticals, Inc.
  5. Communiqués